Nike faces growing speculation over its future in the Dow after being removed from the S&P 100. Its weak share performance, low price and declining market value have raised questions about whether the sportswear giant could eventually exit the blue-chip index.
Middle East conflict-driven energy price spikes and rising global borrowing costs are reviving inflation risks while threatening economic growth. Brent crude remains above $100, government bond yields have surged, and households face higher fuel, energy and mortgage costs. Despite resilient economic activity and AI investment, prolonged pressures could create a challenging stagflationary environment.
Tata Sons’ potential IPO and internal governance dispute are driving volatility across Tata Group stocks, with Tata Chemicals seeing the sharpest moves. Its 2.5% Tata Sons stake is worth about Rs 30,052 crore, exceeding its market capitalization. Investors expect significant value unlocking, while Tata Trusts’ opposition to Chandrasekaran’s reappointment adds uncertainty around the IPO.
Orion180 Insurance raised $240 million through its US IPO after pricing 20 million shares at $12 each, below its targeted range of $15-$17. The insurer is set to list on Nasdaq as the US IPO pipeline gains momentum.
Jefferies has retained its Buy rating on Navin Fluorine International and raised its price target to Rs 9,405, citing growth prospects in CDMO, R32 and the Chemours project. The brokerage expects a 23% EPS CAGR through FY29, while the company’s Q1FY27 profit more than doubled year-on-year to Rs 243 crore.
The SEC has introduced a five-year exemption to facilitate trading in tokenized stocks, allowing certain blockchain-based platforms to operate under limited regulatory relief. The framework gives issuers the right to object to tokenized listings and excludes synthetic stock tokens, while seeking to balance innovation with investor protection and market integrity.
Fourteen stocks held by over 100 mutual fund schemes each surged 60-200% in CY26 through August, with Welspun Corp, Aditya Infotech and Apar Industries among the biggest gainers.
Ultragenyx Pharmaceutical shares surged 12.6% after FDA approval of Fayuvi, its gene therapy for Sanfilippo syndrome Type A, though the RARE stock remains down sharply year-to-date following a failed trial.
MF Performance
Major Indices
